Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs

What Was Tested

In this not phased trial, researchers set out to test Tirzepatide.

These medicines are called incretin-based therapies and include GLP-1 receptor agonists and a newer dual therapy that targets both GIP and GLP-1 receptors.

It had two arms (groups): one (experimental) and one (experimental).

The registry classes the interventions as drug.

More on the Plan

Overview: Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide and in Kazakhstan.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin receptor agonists such as tirzepatide represent a novel class of therapeutics with multimodal actions.

Integration of genomic profiling seeks to identify genetic determinants of therapeutic response, enabling a precision medicine approach and supporting the development of population-specific treatment guidelines.

Scientific Rationale: The pathophysiology of HFpEF and T2DM involves intricate mechanisms, including insulin resistance, chronic low-grade inflammation, endothelial dysfunction, myocardial stiffness, and impaired diastolic relaxation.

Who Took Part

120 planned participants were the target.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Ongoing treatment for T2DM (e.g., metformin and/or sulfonylureas, or basal insulin therapy). Body mass index (BMI) ≥ 25 kg/m². Possible inclusion of patients with chronic pancreatitis in remission. Aged 18 years or older, and not older than 75 years. Both male and female participants.

The full record lists 8 inclusion and 13 exclusion criteria; among the exclusions: type 1 diabetes mellitus; exacerbation of chronic pancreatitis; acute pancreatitis.

How the Study Was Run

It was run as a non-randomized, parallel-group and quadruple-blind study.

Groups ran in parallel: each of the participants stayed in one arm throughout.

As a double-blind Tirzepatide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2024-12-18 with completion listed for 2025-07-01.

It ran at 1 site in Kazakhstan.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Change in NT-proBNP levels from baseline to Week 24 (time frame: Baseline to Week 24).

It also tracked 5 secondary outcomes, for example Assessment of the Overall Condition of Patients Before and After the Study.

What This Means in Plain Language

Put simply, this is a not phased, non-randomized trial of Tirzepatide in 120 people.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.